OBJECTIVES: Budget impact analysis of switching Pramipexole Immediate Release (IR) to Pramipexole Extended Release (ER) in treatment of Parkinson’s Disease in the Turkish healthcare setting from a Social Security Institution’s (SSI) perspective. METHODS: Based upon a literature review demonstrating that, Pramipexole ER is similar to Pramipexole IR in efficacy and safety in treatment of Parkinson’s Disease (non-inferiority), budget impact analyses were performed using Microsoft Excel (2007). RESULTS: The switch from IR to ER was analyzed for the following formulations 0.75MG /1.50MG /3.00MG /4.50MG per day and patient. The daily pill burden per patient was reduced from 3 to 1 and 6 to 1 for 0,75MG /1,5MG /3,0MG and 4,5MG respectively. The total annual treatment cost per patient was reduced by 2.91%, 6.25%, 1.74% and 3.30% for 0.75MG, 1.50MG, 3.00MG and 4.50MG respectively. CONCLUSIONS: The findings of this study indicate that, switching Parkinson’s Patients from Pramipexole IR to ER will not result in an additional budget impact for the Turkish healthcare system from a SSI perspective. However, further research needs to be conducted in order to explore the potential implications of compliance benefits and if they can be translated into long-term savings. LIMITATIONS: No local effectiveness data was available at the time this analysis was performed. Potential benefits in patients’ adherence were not considered.